Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
暂无分享,去创建一个
C. Denkert | H. Oettle | H. Riess | M. Sinn | H. Bläker | P. Lohneis | K. Jöhrens | M. Bahra | U. Pelzer | B. Sinn | J. Striefler | S. Bischoff | A. Jühling | L. Wisłocka
[1] P. Watson,et al. PD-L1 and intratumoral immune response in breast cancer. , 2017, Oncotarget.
[2] R. Muschel,et al. Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma , 2016, Oncotarget.
[3] P. Watson,et al. CD103 and Intratumoral Immune Response in Breast Cancer , 2016, Clinical Cancer Research.
[4] H. Hollema,et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. , 2016, European journal of cancer.
[5] Chun-tao Wu,et al. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma , 2016, The British journal of surgery.
[6] Carsten Denkert,et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] D. Jäger,et al. Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma , 2015, British Journal of Cancer.
[8] S. Endres,et al. Analysis of FoxP3+ T-Regulatory Cells and CD8+T-Cells in Ovarian Carcinoma: Location and Tumor Infiltration Patterns Are Key Prognostic Markers , 2014, PloS one.
[9] R. deLeeuw,et al. Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer , 2013, Clinical Cancer Research.
[10] A. Hinke,et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. , 2013, JAMA.
[11] D. Lobo,et al. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays , 2013, BMC Cancer.
[12] L. De Monte,et al. Immune infiltrates as predictive markers of survival in pancreatic cancer patients , 2013, Front. Physiol..
[13] Y. Kanai,et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer , 2013, British Journal of Cancer.
[14] F. Mami-Chouaib,et al. CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. , 2013, Cancer research.
[15] Carsten Denkert,et al. Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization , 2012, PloS one.
[16] A. Nowak,et al. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8+ T cells in vivo , 2012, Cancer Immunology, Immunotherapy.
[17] N. Jamieson,et al. The Relationship Between Tumor Inflammatory Cell Infiltrate and Outcome in Patients with Pancreatic Ductal Adenocarcinoma , 2012, Annals of Surgical Oncology.
[18] R. Hruban,et al. Loss of E-Cadherin Expression and Outcome among Patients with Resectable Pancreatic Adenocarcinomas , 2011, Modern Pathology.
[19] B. Nelson,et al. Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (alphaE/beta7 Integrin) in high-grade serous ovarian cancer. , 2010, Gynecologic oncology.
[20] T. Tani,et al. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. , 2010, Oncology reports.
[21] A. Dalgleish,et al. Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses , 2009, British Journal of Cancer.
[22] M. Werner,et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes , 2009, British Journal of Cancer.
[23] A. Gemma,et al. Predominant infiltration of macrophages and CD8+ T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer , 2008, Cancer.
[24] V. Lazar,et al. αEβ7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis , 2007, The Journal of experimental medicine.
[25] Peter Neuhaus,et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. , 2007, JAMA.
[26] L. Zitvogel,et al. Cancer despite immunosurveillance: immunoselection and immunosubversion , 2006, Nature Reviews Immunology.
[27] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[28] B. Rasmussen,et al. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays , 2006, Journal of Clinical Pathology.
[29] Z. Trajanoski,et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.
[30] A. Harris,et al. REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British Journal of Cancer.
[31] M. Büchler,et al. Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] T. Oshikiri,et al. CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.
[33] J. Frelinger,et al. Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1 , 2003, The Journal of Immunology.
[34] J. Kirby,et al. T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immunotherapy? , 2002, British Journal of Cancer.
[35] A. Nowak,et al. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. , 2002, Cancer research.
[36] J. Kirby,et al. Distribution of lymphocytes of the αEβ7 phenotype and E‐cadherin in normal human urothelium and bladder carcinomas , 2001 .
[37] P. Schlag,et al. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. , 2001, Cancer research.
[38] C. Cordon-Cardo,et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. , 2001, The American journal of pathology.
[39] Morr.,et al. Expression of mucosa‐related integrin αEβ7 on alveolar T cells in interstitial lung diseases , 1999 .
[40] P. Malfertheiner,et al. CD8+CD103+ T cells analogous to intestinal intraepithelial lymphocytes infiltrate the pancreas in chronic pancreatitis. , 1998 .
[41] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[42] P. Malfertheiner,et al. CD8+CD103+ T cells analogous to intestinal intraepithelial lymphocytes infiltrate the pancreas in chronic pancreatitis* , 1998 .
[43] Yih-Tai Chen,et al. Direct and Regulated Interaction of Integrin αEβ7 with E-Cadherin , 1998, The Journal of cell biology.
[44] P. Karecla,et al. Recognition of E‐cadherin on epithelial cells by the mucosal T cell integrin αM290β7 (αEβ7) , 1995 .
[45] D. Rimm,et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrin , 1994, Nature.
[46] D. Erle,et al. Lung epithelial lining fluid T cell subsets defined by distinct patterns of beta 7 and beta 1 integrin expression. , 1994, American journal of respiratory cell and molecular biology.
[47] J. J. Taylor,et al. T-cell receptor heterogeneity of gamma delta T-cell clones from human female reproductive tissues. , 1993, Immunology.
[48] P. Kilshaw,et al. A new surface antigen on intraepithelial lymphocytes in the intestine , 1990, European journal of immunology.
[49] K. Mizuno,et al. Monoclonal Antibody , 2020, Definitions.
[50] T. Greten,et al. Immunological off-target effects of standard treatments in gastrointestinal cancers. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[51] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[52] C. Lawton,et al. Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer , 2012 .
[53] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] D. Neal,et al. Distribution of lymphocytes of the alpha(E)beta(7) phenotype and E-cadherin in normal human urothelium and bladder carcinomas. , 2001, Clinical and experimental immunology.
[55] W. Seeger,et al. Expression of mucosa-related integrin alphaEbeta7 on alveolar T cells in interstitial lung diseases. , 1999, Clinical and experimental immunology.
[56] P. Karecla,et al. Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). , 1995, European journal of immunology.
[57] D. Rimm,et al. Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin. , 1994, Nature.
[58] C. Griscelli,et al. A monoclonal antibody (HML‐1) defining a novel membrane molecule present on human intestinal lymphocytes , 1987, European journal of immunology.